Patents by Inventor Eun-Kyoung Bang

Eun-Kyoung Bang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12050224
    Abstract: Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: July 30, 2024
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ghil Soo Nam, Hyun Ah Choo, Ahmed A. Elbatrawy, Gyo Chang Keum, Yun Kyung Kim, Sung Su Lim, Jae Kyun Lee, Eun Kyoung Bang
  • Publication number: 20240226287
    Abstract: The present disclosure relates to a novel lipid compound and a lipid nanoparticle composition including the same and, more specifically, the lipid nanoparticle composition includes ionized lipid, helper lipid, PEG-lipid, and additives, and may mitigate changes and side effects in the delivery mechanism and enhance the protein expression efficiency by including a biofriendly vitamin-based novel lipid compound and helper lipids including neutral lipids.
    Type: Application
    Filed: December 12, 2023
    Publication date: July 11, 2024
    Applicants: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Eun-Kyoung Bang, GYO CHANG KEUM, Jae- Hwan Nam, Seohyeon Bae, Muhammad Faisal, Sung Pil Kwon, Soyeon Yoo
  • Publication number: 20230149311
    Abstract: Disclosed is a novel composition of lipid nanoparticles for stabilizing a nucleic acid drug and enhancing delivery in vivo. Lipid nanoparticles include a nucleic acid drug and a lipid, and the nucleic acid includes all of mRNA-based vaccines, RNA for immune boosters, miRNA, siRNA, pDNA, antisense ODN, and pDNA. The lipid of nanoparticles includes a trehalose-based lipid, an ionizable lipid, a phospholipid, a PEG-lipid, and a structure-maintaining lipid. The structure-maintaining lipid provides a composition that can replace commonly used cholesterol with a lithocholic acid derivative, a glycyrrhetinic acid derivative, or a diosgenin derivative. The lipid nanoparticles can be used as a vaccine or therapeutic agent, depending on the type of nucleic acid drug that is used.
    Type: Application
    Filed: February 22, 2022
    Publication date: May 18, 2023
    Inventors: Eun Kyoung BANG, Gyo Chang KEUM, Taek KANG, Byung Sun JEON, An Soo LEE, Jae Hwan NAM, Seo Hyeon BAE
  • Patent number: 11407745
    Abstract: Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: August 9, 2022
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gyo Chang Keum, Ashraf Kareem El-Damasy, Hee Won Jin, Taek Kang, Eun Kyoung Bang
  • Publication number: 20220233700
    Abstract: The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.
    Type: Application
    Filed: May 25, 2020
    Publication date: July 28, 2022
    Applicants: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jae Hwan NAM, Gyo Chang KEUM, Hyo Jung PARK, Eun Kyoung BANG, Hae Li KO
  • Publication number: 20210255203
    Abstract: Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.
    Type: Application
    Filed: September 15, 2020
    Publication date: August 19, 2021
    Inventors: Ghil Soo NAM, Hyun Ah CHOO, Ahmed A. Elbatrawy, Gyo Chang KEUM, Yun Kyung KIM, Sung Su LIM, Jae Kyun LEE, Eun Kyoung BANG
  • Publication number: 20200392127
    Abstract: Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 17, 2020
    Inventors: Gyo Chang KEUM, Ashraf Kareem El-Damasy, Hee Won JIN, Taek KANG, Eun Kyoung BANG
  • Patent number: 10190120
    Abstract: Provided herein are a novel Zn-DPA complex compound and an siRNA delivery system including the same as a transporter, the Zn-DPA complex compound including: a phosphate-directing functional part of zinc (II)-dipicolylamine (“Zn-DPA”); a cell membrane-directing functional part; and a linker part that links the phosphate-directing functional part and the cell membrane-directing functional part. The Zn-DPA complex compound has low toxicity and efficiently delivers siRNA to cells, thereby useful in various ways for various studies and diagnosis and treatment of diseases, which use siRNA.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: January 29, 2019
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gyo Chang Keum, Eun Kyoung Bang, Jin Bum Kim
  • Publication number: 20180044674
    Abstract: Provided herein are a novel Zn-DPA complex compound and an siRNA delivery system including the same as a transporter, the Zn-DPA complex compound including: a phosphate-directing functional part of zinc (II)-dipicolylamine (“Zn-DPA”); a cell membrane-directing functional part; and a linker part that links the phosphate-directing functional part and the cell membrane-directing functional part. The Zn-DPA complex compound has low toxicity and efficiently delivers siRNA to cells, thereby useful in various ways for various studies and diagnosis and treatment of diseases, which use siRNA.
    Type: Application
    Filed: August 8, 2017
    Publication date: February 15, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gyo Chang KEUM, Eun Kyoung BANG, Jin Bum KIM
  • Publication number: 20070015927
    Abstract: Novel phosphoramidites having various functional groups can be advantageously used as new building blocks to synthesize various oligodeoxyribonucleotides which are useful for the development of a highly efficient diagnostic agent and the synthesis of new nano structural oligodeoxyribonucleotides.
    Type: Application
    Filed: April 28, 2003
    Publication date: January 18, 2007
    Inventors: Byeang Kim, Su Kim, Eun-Kyoung Bang